checkAd

    DGAP-News  433  0 Kommentare Biotest AG: Voluntary recall of human albumin - Seite 2



    About Biotest

    Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.



    IR contact

    Dr. Monika Buttkereit

    phone: +49-6103-801-4406

    email: investor_relations@biotest.de

    PR contact

    Dirk Neumüller

    phone: +49-6103-801-269

    email: pr@biotest.com


    Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com



    Ordinary shares: securities' ID No. 522720; ISIN DE0005227201

    Preference shares: securities' ID No. 522723; ISIN DE0005227235

    Listing: Prime Standard

    Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart



    Disclaimer

    This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

    Seite 2 von 3



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Biotest AG: Voluntary recall of human albumin - Seite 2 DGAP-News: Biotest AG / Key word(s): Profit Warning Biotest AG: Voluntary recall of human albumin 26.04.2017 / 17:48 The issuer is solely responsible for the content of this announcement. / PRESS RELEASEBiotest: Voluntary recall of human albumin - …